Formulation of adenovirus for gene therapy

Details Formulation of adenovirus for gene therapy Formulation of adenovirus for gene therapy

2007-06-26

2007-06-26

Zeman, Robert A. (Department: 1645)

Chemistry: molecular biology and microbiology

Virus or bacteriophage, except for viral vector or...

C435S239000, C435S243000, C435S260000

Reexamination Certificate

active

09941296

ABSTRACT:
The present invention addresses the need to improve the long-term storage stability (i.e. infectivity) of vector formulations. In particular, it has been demonstrated that for adenovirus, the use of bulking agents, cryoprotectants and lyoprotectants imparts desired properties that allow both lyophilized and liquid adenovirus formulations to be stored at 4° C. for up to 6 months and retain an infectivity between 60–100% of the starting infectivity.

REFERENCES:
patent: 4352883 (1982-10-01), Lim
patent: 4725547 (1988-02-01), Sakamoto et al.
patent: 4797368 (1989-01-01), Carter et al.
patent: 5139941 (1992-08-01), Muzycka et al.
patent: 5552309 (1996-09-01), March
patent: 5607851 (1997-03-01), Pellegrini et al.
patent: 5744304 (1998-04-01), Munford
patent: 5789244 (1998-08-01), Heidrum et al.
patent: 5837520 (1998-11-01), Shabram et al.
patent: 6143290 (2000-11-01), Zhang et al.
patent: 6168944 (2001-01-01), Condon et al.
patent: 6194210 (2001-02-01), Leu et al.
patent: 6383795 (2002-05-01), Carrión et al.
patent: 6485958 (2002-11-01), Blanche et al.
patent: 6537793 (2003-03-01), Blanche et al.
patent: 6586226 (2003-07-01), Carrion et al.
patent: 6689600 (2004-02-01), Wu et al.
patent: 2002/0018723 (2002-02-01), Mera et al.
patent: 2002/0094577 (2002-07-01), Guirguis et al.
patent: 0273085 (1988-07-01), None
patent: 0475623 (1992-03-01), None
patent: 1279843 (1989-11-01), None
patent: 4-9338 (1992-01-01), None
patent: WO 93/18790 (1993-09-01), None
patent: WO 93/25224 (1993-12-01), None
patent: WO 94/06910 (1994-03-01), None
patent: WO 94/17178 (1994-08-01), None
patent: WO 95/06743 (1995-03-01), None
patent: WO 95/10601 (1995-04-01), None
patent: WO 95/19427 (1995-07-01), None
patent: WO 95/25789 (1995-09-01), None
patent: WO 96/09399 (1996-03-01), None
patent: WO 96/27677 (1996-09-01), None
patent: WO 96/32116 (1996-10-01), None
patent: WO 97/04803 (1997-02-01), None
patent: WO 97/08298 (1997-03-01), None
patent: WO 98/00524 (1998-01-01), None
patent: WO 98/22588 (1998-05-01), None
patent: WO 98/26048 (1998-06-01), None
patent: WO 98/35554 (1998-08-01), None
patent: WO 99/12568 (1999-03-01), None
patent: WO 99/41416 (1999-08-01), None
patent: WO 99/54441 (1999-10-01), None
patent: WO 00/32754 (2000-06-01), None
patent: WO 00/34444 (2000-06-01), None
Cartwright, T.,Animal cells as bioreactors, In: Cambridge Studies in Biotechnologyt, Cambridge University Press, No. 11:58-63, 1994.
Haruna et al., “Separation of adenovirus by chromatography on DEAE-cellulose,” Virology, 13:264-267, 1961.
Aboud et al., “Rapid purification of extracellular and intracellular moloney murine leukemia virus,”Arch. Virol., 71:185-195, 1982.
Baichwal and Sugden,In: Kucherlapati R, ed. Gene transfer. New York: Plenum Press, 117-148, 1986.
Benvenisty and Reshef, “Direct introduction of genes into rats and expression of the genes,”Proc. Nat'l Acad. Sci. USA, 83:9551-9555, 1986.
Berg et al., “High-level expression of secreted proteins from cells adapted to serum-free suspension culture,”BioTechniques, 14(6):972-978, 1993.
Bett, “An efficient and flexible system for construction of adenovirus vectors with insertions or deletions in early regions 1 and 3,”Proc. Natl. Acad. Sci. USA, 91(19):8802-8806, 1994.
Bussemakers et al., “Decreased expression of E-cadherin in the progression of rat prostatic cancer,”Cancer Res., 52:2916-2922, 1992.
Cartwright, “Fermenter design for animal cell cultures,” Animal Cells as Bioreactors, Cambridge University Press, 58-63, 1994.
Casey et al., “Growth suppression of human breast cancer cells by the introduction of a wild-type p53 gene,”Oncogene, 6:1791-1797, 1991.
Chen and Okayama, “High-efficiency transfection of mammalian cells by plasmid DNA,”Mol. Cell Biol.7:2745-2752, 1987.
Cheung et al., “Cell-CAM105 isoforms with different adhesion functions are coexpressed in adult rat tissues and during liver development”,J. Biol. Chem.,268:6139-6146, 1993.
Cheung et al., “The cytoplaxmic domain of C-CAM is required for C-CAM-mediated adhesion function: studies of a C-CAM transcript containing an unspliced intron”,Biochem. J.,295:427-435, 1993.
Coffin, “Retroviidae and their replication,”In: Virology, Fields et al. (eds.), New York: Raven Press, pp. 1437-1500, 1990.
Complaint Aventis Pharmaceuticals Products Inc. and Aventis Pharma, S.A., Plaintiffs, v. Introgen Therapeutics, Inc., Defendant. Civil Action No. 01-451 from the U.S. District Court for the District of Delaware, Jun. 29, 2001.
Coupar et al., “A general method for the construction of recombinant vaccinia virus expressing multiple foreign genes,”,Gene, 68:1-10, 1988.
Crooks et al., “Purification and analysis of infections virions and native non-structural antigens from cells infected with tick-borne encephalitis virus,”J. Chrom.,502:59-68, 1990.
Dubensky et al., “Direct transfection of viral and plasmid DNA into the liver of spleen of mice,”Proc. Nat. Acad. Sci. USA, 81:7529-7533, 1984.
Edelman and Crossin, “Cell adhesion molecules: implications for a molecular histology,”Annu. Rev. Biochem., 60:155-190, 1991.
Edelman, “Cell adhesion and the molecular processes of morphogenesis,”Annu. Rev. Biochem.,54:135-169, 1985.
Fechheimer et al., “Transfection of mammalian cells with plasmid DNA by scrape loading and sonication loading,”Proc. Nat'l Acad. Sci. USA, 84:8463-8467, 1987.
Fraley et al., “Entrapment of a bacterial plasmid in phospholipid vesicles: Potential for gene transfer,”Proc. Nat'l Acad. Sci. USA, 76:3348-3352, 1979.
Freshney, “Animal Cell Culture: a Practical Approach,” Second Edition, Oxford/New York, IRL Press, Oxford University Press, 1992.
Frixen et al., “E-cadherin-mediated cell-cell adhesion prevents invasiveness of human carcinoma cells,”J. Cell Biol., 113:173-185, 1991.
Garnier et al., “Scale-up of the adenovirus expression system for the production of recombinant protein in human 293S cells,”Cytotechnol., 15:145-155, 1994.
Ghosh and Bachhawat,In: Liver Diseases, Targeted Diagnosis and Therapy Using Specific Receptors and Ligands, Wu G, Wu C (ed).), Marcel Dekker, New York, 87-104, 1991.
Giancotti and Ruoslahti, “Elevated levels of the α5β1fibronectin receptor suppress the transformed phenotype of Chinese hamster ovary cells,”Cell, 60:849-859, 1990.
Gilbert, “Adaption of cells to serum free culture for production of adenovirus vectors and recombinant proteins,”Williamsburg BioProcessing Conference, Nov. 18-21, 1996.
Gopal, “Gene transfer method for transient gene expression, stable transfection, and contransfection of supension cell cultures,”Mol. Cell Biol.,5:1188-1190, 1985.
Graham and Prevec, “Manipulation of adenovirus vectors,”In: Methods in Molecular Biology: Gene Transfer and Expression Protocols 7, (Murray, Ed.), Humana Press, Clifton, NJ, 109-128, 1991.
Graham and Van Der Eb, “A new technique for the assay of infectivity of human adenovirus 5 DNA,”Virology, 52:456-467, 1973.
Graham et al, “Characteristics of a human cell line transformed by DNA from human adenovirus type 5,”J. Gen. Virol., 36:59-72, 1977.
Graham, “Growth of 293 Cells in Suspension Culture,”J. Gen. Virol., 68:937-940, 1987.
Griffiths, “Overview of cell culture systems and their scale-up,”In: Animal Cell Biotechnology, vol. 3, p. 179-220, (Spier and Griffiths, eds.), Academic Press, London, 1986.
Harland and Weintraub, “Translation of mammalian mRNA injected intoXenopusoocytes is specifically inhibited by antisense RNA,”J. Cell Biol., 101:1094-1099, 185.
Hay et al., “Replication of adenovirus mini-chromosomes,”J. Mol. Biol., 175:493-510, 1984.
Hearing and Shenk, “Functional analysis of the nucleotide sequence surrounding the cap site for adenovirus type 5 region E1A

Affiliated with

Also associated with

Rating

Formulation of adenovirus for gene therapy does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Formulation of adenovirus for gene therapy, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Formulation of adenovirus for gene therapy will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3845792